Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi-MedImmune RA Biologic Approved for China Trials

publication date: Jan 18, 2017
The novel rheumatoid arthritis biologic partnered by WuXi AppTec and MedImmune has been granted CFDA permission to begin clinical trials. The approval came almost two years after the CFDA accepted the molecule's IND filing. The candidate, WBP216 (MEDI5117), is a novel anti-IL-6 antibody that MedImmune modified for extended duration of action. In China, it is a class 1 innovative biologic. The WuXi-MedImmune China JV, which was set up in 2012, is in charge of developing the drug for China. MedImmune is the biologics arm of AstraZeneca. More details....

Stock symbol: (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital